Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

DCAT Week ’17 Member Company Announcement Forum: Tracking the Pharma Manufacturing Value Chain

Senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions, at the DCAT Member Company Announcement Forum at DCAT Week ’17. DCAT Value Chain Insights highlights the latest developments.

Developments in Drug-Substance Manufacturing
Noramco CEO Discusses Strategy as Stand-Alone Company

Patheon Integrates Former Roche API Manufacturing Facility

BioVectra Outlines API Manufacturing Expansion

Novasep Opens New Bioconjugation Facility for ADCs

Olon Highlights Integration of Infa

CMC Biologics Updates Acquisition by AGC Asahi Glass

Developments in Drug-Product Development and Manufacturing
Mayne Pharma Specifies Timeline for $80-Million Expansion

Catalent Integrates Pharmatek and Accucaps Acquisitions

Lubrizol’s Particle Sciences Expands Manufacturing

Developments in both Drug Substance and Drug Product Manufacturing:
Siegfried CEO Outlines Five-Year Strategic Plan

CordenPharma Expands Oligonucletides and Sterile Injectables

Developments in Packaging
Datwyler Outlines $100-Million Manufacturing Expansion

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The Top 25 Supply Chain Organizations: Where Does Pharma Rank?

By
Which companies have the highest ranked global supply-chain organizations? Three bio/pharma companies made the cut in the Gartner Group’s annual ranking of the top 25 supply-chain organizations. Who are they. and what does it take to be in the top?

Raw Materials Outlook: A Macro View: GDP, Energy & Slowing Inflation

By
High energy costs and inflationary pressures had a major impact on raw materials supply post-pandemic, but what do key macroeconomic indicators now show? Will the moderate growth and slowing inflation seen in the first half of 2024 continue in the near term?

EU Tackles Drug Supply-Chain Vulnerabilities: Is Onshoring in Play?

By
The European Commission has released results from a pilot study evaluating the supply-chain vulnerabilities of 11 critical medicines, including manufacturing dependencies of APIs from outside the EU. What did the study show, and what is next?

Innovation Scorecard: The New Drug Approvals Thus Far in 2024

By
As we move past the mid-way mark in 2024, how has the industry fared with new drug approvals? Is the industry keeping pace with prior years’ innovation levels? What is the mix between small molecules and biologics, and which companies are meeting the mark?